Biomea Fusion, Inc. (BMEA) company profile
Close on Nov 12, 2026Market cap $40.79MP/E –Yield –
About Biomea Fusion
Pharmaceutical Preparations, SIC 2834
Biomea Fusion is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule therapies for metabolic conditions. The organization focuses on treatments for type 1 diabetes, type 2 diabetes, and obesity. Its research pipeline centers on two core investigational programs: icovamenib, an oral covalent menin inhibitor under study for diabetes and obesity, and BMF-650, an oral glucagon-like peptide-1 receptor agonist in development for obesity. The company has no commercialized products, and its investigational therapies target patient populations suffering from diabetes and metabolic disorders.
The company is headquartered in San Carlos, California, where it maintains its principal executive offices. Its workforce consists of approximately 40 employees who support research, clinical development, clinical operations, clinical pharmacology, regulatory affairs, pharmacovigilance, and quality functions. The company operates within the United States, and the provided report identifies no additional operating facilities, stores, or international offices.
Summary of the business section of Biomea Fusion's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biomea Fusion, Inc.
- Founded
- 2017
- Headquarters
- San Carlos, CA
- Address
- 1599 Industrial Road 94070
- Phone
- (650) 980-9099
- Website
- biomeafusion.com
- Employees
- 41, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, CA
Stock & identifiers
- Ticker
- BMEA
- Exchange
- Nasdaq
- IPO date
- Apr 19, 2021
- Shares outstanding
- 72M, Jul 31, 2026
- Public float
- $93.61M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1840439
- CUSIP
- 09077A106
- ISIN
- US09077A1060
- FIGI
- BBG00YS4WDC9
- Share class FIGI
- BBG00YS4WDD8
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael J.M. Hitchcock | Interim CEO, Director | 115,000 |
| Rainer M. Erdtmann | See Remarks, Director | 987,041 |
| Franco Valle | Chief Financial Officer | 42,995 |
| Julianne Averill | Director | – |
| Eric Aguiar | Director | – |
| Elizabeth Faust | Director | – |
| Sumita Ray | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Michael J.M. Hitchcock Interim Chief Executive Officer and Principal Executive Officer | $486.74K | $220.08K | $1.85M | $14.13K | $2.57M | – |
| Rainer (Ramses) Erdtmann Chief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer | $489.60K | $146.88K | $1.57M | – | $2.21M | +12% |
| Thomas Butler Former Chief Executive Officer and Former Chairman of the Board | $148.80K | – | – | $513.16K | $661.96K | -87% |
| Juan Pablo Frias Former Chief Medical Officer | $325.00K | – | $158.71K | $65.33K | $549.04K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 19, 2021
- Offer price
- $17.00
- Securities offered
- 9,000,000
- Gross proceeds
- $153.00M
- Exchange
- Nasdaq
- First trading day
- Apr 16, 2021
- First-day close
- $18.60+9.4%
- Lock-up ends (est.)
- Oct 13, 2021
“The initial public offering price is $17.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 41 full-time employees, 27 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 27, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 19, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?